Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALENTINO maintenance study in RAS wild-type metastatic colorectal cancer
2015-000333-71Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab, fluorouracil, folinic acid and oxaliplatin in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-free survival. Started Jan 2021; status: completed.
02
Drugs
panitumumabfluorouracilfolinic acidoxaliplatin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2015-000333-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000333-71.